A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Description

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it

Conditions

Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Condition
Non-alcoholic Fatty Liver Disease
Intervention / Treatment

-

Contacts and Locations

Chandler

The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0, Chandler, Arizona, United States, 85224

Flagstaff

Arizona Clinical Trials ( Site 0158), Flagstaff, Arizona, United States, 86001

Peoria

The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120), Peoria, Arizona, United States, 85381

Tucson

The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 0111), Tucson, Arizona, United States, 85712

Pasadena

California Liver Research Institute ( Site 0113), Pasadena, California, United States, 91105

San Diego

Acclaim Clinical Research ( Site 0137), San Diego, California, United States, 92120

Van Nuys

Velocity Clinical Research, Panorama City ( Site 0124), Van Nuys, California, United States, 91405

Bradenton

Synergy Healthcare ( Site 0118), Bradenton, Florida, United States, 34208

Homestead

Homestead Associates in Research, Inc. ( Site 0139), Homestead, Florida, United States, 33033

Lakewood Ranch

Florida Research Institute ( Site 0116), Lakewood Ranch, Florida, United States, 34211

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)
  • * Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes
  • * Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease
  • * Has history of type 1 diabetes
  • * Had a bariatric surgical procedure less than 5 years before entry into the study
  • * History of pancreatitis
  • * Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Merck Sharp & Dohme LLC,

Medical Director, STUDY_DIRECTOR, Merck Sharp & Dohme LLC

Study Record Dates

2026-05-15